Compare Stocks → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:ALNANYSEAMERICAN:ARMPNASDAQ:BCDANASDAQ:MBOT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$11.75$0.61▼$24.20$820K1.4119,299 shs416,900 shsALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsARMPArmata Pharmaceuticals$2.55+2.0%$0.00$1.07▼$5.26$92.18M0.8517,667 shs31,015 shsBCDABioCardia$0.38+2.7%$0.42$0.36▼$2.92$10.13M1.47337,584 shs62,010 shsMBOTMicrobot Medical$0.89-1.1%$1.21$0.86▼$4.37$12.82M1.64124,676 shs211,341 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%-24.86%-95.10%-96.22%-93.71%ALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARMPArmata Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BCDABioCardia+1.04%-7.98%-4.71%-36.02%-81.60%MBOTMicrobot Medical-5.14%-18.92%-17.43%-32.84%-50.82%[Urgent!] Generational Wealth Gameplan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AARMPArmata Pharmaceuticals2.0827 of 5 stars3.53.00.00.01.91.70.6BCDABioCardia1.6792 of 5 stars3.35.00.00.00.02.50.0MBOTMicrobot Medical1.4384 of 5 stars3.53.00.00.02.20.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AARMPArmata Pharmaceuticals3.00Buy$7.00174.51% UpsideBCDABioCardia2.50Moderate Buy$4.00961.01% UpsideMBOTMicrobot Medical3.00Buy$7.00686.52% UpsideCurrent Analyst RatingsLatest ACOR, MBOT, BCDA, ALNA, and ARMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.003/22/2024ARMPArmata PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00ALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/AARMPArmata Pharmaceuticals$4.53M20.35N/AN/A($0.89) per share-2.87BCDABioCardia$480K21.10N/AN/A($0.07) per share-5.39MBOTMicrobot MedicalN/AN/AN/AN/A$0.38 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)ALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/AARMPArmata Pharmaceuticals-$69.04M-$1.98N/AN/AN/A-1,524.51%-280.95%-52.61%5/9/2024 (Estimated)BCDABioCardia-$11.57M-$0.55N/AN/AN/A-2,425.79%-3,638.68%-228.55%5/8/2024 (Estimated)MBOTMicrobot Medical-$10.74M-$1.08N/A∞N/AN/A-164.13%-125.22%5/15/2024 (Estimated)Latest ACOR, MBOT, BCDA, ALNA, and ARMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023ARMPArmata PharmaceuticalsN/A-$0.55-$0.55-$0.55$0.68 million$1.53 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AARMPArmata PharmaceuticalsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26ALNAAllena PharmaceuticalsN/A1.581.58ARMPArmata PharmaceuticalsN/A1.161.16BCDABioCardiaN/A0.400.40MBOTMicrobot MedicalN/A2.092.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%ALNAAllena Pharmaceuticals7.33%ARMPArmata Pharmaceuticals3.57%BCDABioCardia20.57%MBOTMicrobot Medical16.30%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%ALNAAllena Pharmaceuticals3.70%ARMPArmata Pharmaceuticals85.50%BCDABioCardia23.90%MBOTMicrobot Medical10.64%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableARMPArmata Pharmaceuticals6636.15 million5.24 millionNot OptionableBCDABioCardia1626.87 million20.34 millionOptionableMBOTMicrobot Medical1814.40 million12.87 millionOptionableACOR, MBOT, BCDA, ALNA, and ARMP HeadlinesSourceHeadlineMicrobot Medical (MBOT) Price Target Decreased by 12.50% to 7.14msn.com - April 18 at 7:13 AMAnalysts Offer Predictions for Microbot Medical Inc.'s Q1 2024 Earnings (NASDAQ:MBOT)americanbankingnews.com - April 18 at 5:46 AMMicrobot Medical (NASDAQ:MBOT) Price Target Cut to $7.00 by Analysts at HC Wainwrightamericanbankingnews.com - April 17 at 3:48 AMAnalysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)markets.businessinsider.com - April 16 at 5:45 PMMicrobot Medical Shares Status Following Recent Geopolitical Eventsglobenewswire.com - April 15 at 8:30 AMMicrobot Medical Inc. (NASDAQ:MBOT) Short Interest Updateamericanbankingnews.com - April 12 at 4:26 AMMicrobot Medical (NASDAQ:MBOT) & Alpha Tau Medical (NASDAQ:DRTS) Financial Analysisamericanbankingnews.com - April 9 at 4:16 AM3 AI Stocks Wall Street Expects to Return Up to 595% in 2024msn.com - March 28 at 10:05 AMMBOT Stock Earnings: Microbot Medical Misses EPS for Q4 2023investorplace.com - March 27 at 11:03 PMMBOT Apr 2024 3.000 callca.finance.yahoo.com - March 16 at 10:15 AMMicrobot Medical Stock (NASDAQ:MBOT) Dividends: History, Yield and Datesbenzinga.com - February 26 at 1:07 AMMBOT Jul 2024 2.500 putfinance.yahoo.com - February 21 at 2:27 AMMBOT Apr 2024 5.000 callfinance.yahoo.com - February 21 at 2:27 AMMBOT Mar 2024 2.500 callfinance.yahoo.com - February 18 at 3:16 PMMicrobot Medical Inc.: Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the USfinanznachrichten.de - February 5 at 12:27 PMMicrobot Medical submits surgical robot for FDA IDEmassdevice.com - February 5 at 12:27 PMMicrobot files FDA application for clinical study of Liberty systemmsn.com - February 5 at 12:27 PMMicrobot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the USfinance.yahoo.com - February 5 at 12:27 PMLooking Into Microbot Medical's Recent Short Interestbenzinga.com - February 2 at 1:43 PMMicrobot Medical Settles: Regulation FD Disclosure Updatemsn.com - January 31 at 6:41 PMMicrobot Medical Inc.: Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Mattersfinanznachrichten.de - January 30 at 4:59 PMMicrobot Medical announces settlement resolving legal mattersmsn.com - January 30 at 9:28 AMMicrobot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Mattersfinance.yahoo.com - January 30 at 9:28 AMMicrobot Medical expands U.S. operations to prep for first in-human clinical studytherobotreport.com - January 24 at 12:41 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit Upside3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AIAll Headlines Company DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Allena PharmaceuticalsNASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Armata PharmaceuticalsNYSEAMERICAN:ARMPArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.BioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.Microbot MedicalNASDAQ:MBOTMicrobot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.